Sudden Cardiac Death News and Research

RSS

The term sudden cardiac death refers to natural death from cardiac causes, heralded by abrupt loss of consciousness within one hour of the onset of acute symptoms.

FDA approves Boston Scientific's latest generation of defibrillators and heart failure devices

Boston Scientific Corporation has received FDA approval for its latest generation of defibrillators and heart failure devices designed to advance patient care. The newly approved devices include the DYNAGEN MINI and INOGEN MINI ICDs, as well as the DYNAGEN X4 and INOGEN X4 CRT-Ds.

16 Apr 2014

Boston Scientific to launch of S-ICD System into parts of Asia

Boston Scientific Corporation (NYSE: BSX) has expanded the launch of its S-ICD System into parts of Asia. The first implant of the S-ICD System in Asia was performed in Hong Kong by Prof. Hung Fat Tse, Professor of Cardiovascular Medicine, The University of Hong Kong and Department of Medicine, Queen Mary Hospital in Pokfulam, Hong Kong, under the proctorship of Dr. Martin Stiles, Director of Electrophysiology, Waikato Hospital in Hamilton, New Zealand.

8 Apr 2014

Researcher finds simple blood test that predicts person's risk for sudden cardiac death

A researcher at the Cardiovascular Institute (CVI) at Rhode Island, The Miriam and Newport hospitals has found that a simple blood test can predict a person's risk for sudden cardiac death, enabling physicians to more quickly and accurately assess a patient's need for an implantable cardiac defibrillator (ICD).

3 Apr 2014

Takeda to present results from global EXAMINE CV safety outcomes trial at ACC 2014

Takeda Pharmaceuticals Company Limited will present sub-analyses from the global EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) cardiovascular (CV) safety outcomes trial in a poster session at the American College of Cardiology’s 63rd Annual Scientific Session in Washington, DC.

28 Mar 2014

ZS Pharma starts patient enrollment in ZS-9 Phase 3 trial for treatment of hyperkalemia

ZS Pharma, a specialty pharmaceutical company developing novel treatments for kidney, cardiovascular and liver disorders, today announced that it has begun enrolling patients in ZS004, its second Phase 3 clinical trial of ZS-9, a novel investigational treatment for hyperkalemia.

25 Mar 2014

Scientists explore link between SCN10A and cardiac arrhythmia risk

Although genome-wide association studies have linked DNA variants in the gene SCN10A with increased risk for cardiac arrhythmia, efforts to determine the gene's direct influence on the heart's electrical activity have been unproductive. Now, scientists from the University of Chicago have discovered that these SCN10A variants regulate the function of a different gene, SCN5A, which appears to be the primary gene responsible for cardiac arrhythmia risk.

21 Mar 2014

Scientists throw light on genetic mutation that causes particularly severe genetic disease ARVC5

The genetic disease ARVC leads to sudden cardiac death and is more common than it has been hitherto assumed. This is reported by an international team of researchers headed by Prof Dr Hendrik Milting from the Heart and Diabetes Center NRW in the "European Heart Journal".

7 Mar 2014

Scientists throw light on genetic mutation that causes ARVC5 in Newfoundland

Scientists have thrown light on the genetic mutation that causes a particularly severe genetic disease (ARVC5) on the Canadian island Newfoundland in 2008.

6 Mar 2014

New class of drugs developed to treat cancer, reduces sudden cardiac death risk after heart attack

A researcher at the Cardiovascular Institute (CVI) at Rhode Island, The Miriam and Newport hospitals has found that a new class of drugs, originally developed to treat cancer, reduces sudden cardiac death risk after a heart attack. The findings were published online in advance of print in the Journal of the American College of Cardiology.

25 Feb 2014

Researchers find new drug compound that treats laboratory mice with congenital heart disease

Congenital heart disease is the most common form of birth defect, affecting one out of every 125 babies, according to the National Institutes of Health. Researchers from the University of Missouri recently found success using a drug to treat laboratory mice with one form of congenital heart disease, hypertrophic cardiomyopathy - a weakening of the heart caused by abnormally thick muscle.

23 Feb 2014

Discovery could lead to improved early detection, prevention strategies for sudden cardiac death

UC Irvine researchers have found a specific genetic flaw that is connected to sudden death due to heart arrhythmia - a leading cause of mortality for adults around the world.

18 Feb 2014

Focused ultrasound exam may accurately identify athletes with heart problems

A young athlete in seemingly excellent health dies suddenly from a previously undetected cardiovascular condition such as hypertrophic cardiomyopathy in nearly every U.S. state annually.

25 Jan 2014

Focused ultrasound exam accurately identifies heart problems in athletes

A young athlete in seemingly excellent health dies suddenly from a previously undetected cardiovascular condition such as hypertrophic cardiomyopathy in nearly every U.S. state annually.

24 Jan 2014

Conventional echocardiography increases accuracy of pre-participation sports screening

Echocardiography with conventional M-mode and 2D modalities is a simple and cost effective way to increases the accuracy of pre-participation sports screening, according to research presented at EuroEcho-Imaging 2013 by Dr Alexander Kisko from Presov, Slovakia.

14 Dec 2013

Research findings suggest possible novel strategies to prevent SUDEP

Patients with epilepsy and, in particular, those with severe syndromic forms of the disorder, harbor a risk of sudden unexplained death in epilepsy, or SUDEP. Cardiac arrhythmias are a proposed cause. In a test of this theory, researchers have demonstrated that mice harboring a human SCN1A gene mutation that results in Dravet Syndrome, a severe and intractable genetic epilepsy, have electrical disturbances in the heart that culminate in ventricular fibrillation and sudden cardiac death.

9 Dec 2013

Study: Unfolded protein response can increase risk of sudden cardiac death

A researcher at the Cardiovascular Institute (CVI) at Rhode Island, The Miriam and Newport hospitals has found a link to human heart failure that if blocked, may reduce the risk of sudden cardiac death.

3 Dec 2013

Long-term use of PDE3 inhibitors can lead to increased risk for sudden cardiac death

Drugs known as PDE3 inhibitors save many lives by helping failing hearts do a better job of pumping blood. But those same medications come with a sometimes deadly cost when taken for long periods: an increased risk for sudden cardiac death.

19 Nov 2013

Cvrx closes additional $12 million under its Series F financing

CVRx, Inc., a privately held medical device company, has closed on an additional $12 million under its Series F financing. This brings the total raised in the Series F financing to $42 million.

30 Oct 2013

High levels of omega-3 fatty acid consumption may lead to unintended health consequences

A new review suggests that omega-3 fatty acids taken in excess could have unintended health consequences in certain situations, and that dietary standards based on the best available evidence need to be established.

29 Oct 2013

CDC and NIH collaborate to create Sudden Death in Young Registry

A registry of deaths in young people from conditions such as heart disease and epilepsy is being created to help researchers define the scope of the problem and set future research priorities. The National Institutes of Health and the Centers for Disease Control and Prevention are collaborating to create the Sudden Death in the Young Registry.

24 Oct 2013